A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
7actual
Sites
4
Country
Taiwan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-22 | actual | When the study began enrolling |
| Primary completion | 2025-03-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-17 | actual | The whole study's end, after follow-up |
| First posted | 2023-12-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapsed or Refractory Multiple Myeloma
Interventions
- Drug: Elotuzumab in combination with pomalidomide and dexamethasone
- Drug: Elotuzumab in combination with lenalidomide and dexamethasone
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events
measured 25 weeks from start of treatment, or during a 30-day follow-up period following treatment discontinuation (whichever time period falls at a later date)
Number of participants with adverse events of special interest
measured 25 weeks from start of treatment, or during a 30-day follow-up period following treatment discontinuation (whichever time period falls at a later date)
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed